We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

50 hedge funds and large institutions have $93M invested in VanEck Pharmaceutical ETF in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

4% more funds holding

Funds holding: 48 → 50 (+2)

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

22.17% less ownership

Funds ownership: 55.6% → 33.43% (-22%)

32% less capital invested

Capital invested by funds: $136M → $93M (-$43.1M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $339K

Holders
50
Holders Change
+2
Holders Change %
+4.17%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
14
Reduced
15
Closed
5
Calls
–
Puts
$339K
Net Calls
-$339K
Net Calls Change
-$206K

Top Buyers

Rank Fund Capital Flow
1
BCI
Brinker Capital Investments
Pennsylvania
+$7M
2
TRCT
Tower Research Capital (TRC)
New York
+$1.72M
3
Jane Street
Jane Street
New York
+$1.26M
4
Morgan Stanley
Morgan Stanley
New York
+$1.23M
5
Citigroup
Citigroup
New York
+$1M

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$64.8M
2
Goldman Sachs
Goldman Sachs
New York
-$5.78M
3
SG Americas Securities
SG Americas Securities
New York
-$5.73M
4
UBS Group
UBS Group
Switzerland
-$1.37M
5
CC
Colrain Capital
Massachusetts
-$578K
Name Holding Trade Value Shares
Change 		Change in
Stake
KFC
26
Klingenstein Fields & Co
New York
$225K – – –
SG Americas Securities
27
SG Americas Securities
New York
$216K -$5.73M -100,000 -96%
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$172K -$5.16K -90 -3%
LTFS
29
Ladenburg Thalmann Financial Services
Florida
$164K -$36.1K -630 -19%
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Quebec, Canada
$142K – – –
JP Morgan Chase
31
JP Morgan Chase
New York
$116K -$11.5K -200 -9%
AG
32
Advisor Group
Arizona
$86K +$82.3K +1,435 +7,972%
NL
33
NVWM LLC
Pennsylvania
$78K +$75.2K +1,312 New
TCM
34
Tradewinds Capital Management
Washington
$71K – – –
GT
35
Glenmede Trust
Pennsylvania
$59K – – –
ASN
36
Advisory Services Network
Georgia
$52K +$57 +1 +0.1%
MIM
37
Macroview Investment Management
Maryland
$45K +$57 +1 +0.1%
HCM
38
Highlander Capital Management
New Jersey
$44K – – –
NSIM
39
North Star Investment Management
Illinois
$30K -$5.05K -88 -15%
JCM
40
Jacobi Capital Management
Pennsylvania
$27K +$22.9K +400 +930%
Carson Wealth (CWM LLC)
41
Carson Wealth (CWM LLC)
Nebraska
$24K – – –
WWM
42
Willingdon Wealth Management
North Carolina
$20K – – –
CPA
43
Clear Perspective Advisors
Illinois
$18K – – –
FAAS
44
First Allied Advisory Services
California
$18K +$17.9K +313 New
ADL
45
Asset Dedication LLC
California
$10K – – –
IA
46
IFP Advisors
Florida
$9K – – –
FANJ
47
Financial Architects (New Jersey)
New Jersey
$4K – – –
AIM
48
Anchor Investment Management
South Carolina
$3.44K +$3.33K +58 New
BFEC
49
Benjamin F. Edwards & Company
Missouri
$1K – – –
CC
50
Colrain Capital
Massachusetts
– -$578K -10,000 Closed
1
2
3

PPH Hedge Fund Activity: Q4 2017 in Review

50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2017, worth a combined $93M — down 32% from $136M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PPH positions and 5 closed out — a net gain of 2 holders — while 14 added to existing stakes and 15 trimmed.

The largest buyer was Brinker Capital Investments, adding an estimated $7M. The largest seller was Bank of America, cutting an estimated $64.8M.

  • 50 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2017, up from 48 in Q3 2017.
  • Funds reported $93M of VanEck Pharmaceutical ETF stock for Q4 2017, down 32% quarter-over-quarter.
  • 7 funds opened new VanEck Pharmaceutical ETF positions in Q4 2017 and 5 closed out, a net change of +2 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2017 was Brinker Capital Investments, an estimated $7M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2017 was Bank of America, an estimated $64.8M sold.

Based on aggregated 13F filings for Q4 2017.